{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T04:25:49Z","timestamp":1771043149843,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,12,2]],"date-time":"2010-12-02T00:00:00Z","timestamp":1291248000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Chem Res"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s00044-010-9510-3","type":"journal-article","created":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T02:42:52Z","timestamp":1291171372000},"page":"133-144","source":"Crossref","is-referenced-by-count":25,"title":["QSAR analysis of 2-benzoxazolyl hydrazone derivatives for anticancer activity and its possible target prediction"],"prefix":"10.1007","volume":"21","author":[{"given":"N. S.","family":"Hari Narayana Moorthy","sequence":"first","affiliation":[]},{"given":"Nuno S.","family":"Cerqueira","sequence":"additional","affiliation":[]},{"given":"Maria J.","family":"Ramos","sequence":"additional","affiliation":[]},{"given":"Pedro A.","family":"Fernandes","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2010,12,2]]},"reference":[{"key":"9510_CR1","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1016\/S0968-0896(01)00241-3","volume":"9","author":"VK Agrawal","year":"2001","unstructured":"Agrawal VK, Srivastava R, Khadikar PV (2001) QSAR studies on some antimalarial sulfonamides. Bioorg Med Chem 9:3287\u20133293","journal-title":"Bioorg Med Chem"},{"key":"9510_CR2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1093-3263(01)00123-1","volume":"20","author":"G Alexander","year":"2002","unstructured":"Alexander G, Alexander T (2002) Beware of Q2. J Mol Graphs Model 20:269\u2013276","journal-title":"J Mol Graphs Model"},{"key":"9510_CR3","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.1016\/j.bmcl.2004.09.068","volume":"14","author":"S Balaji","year":"2004","unstructured":"Balaji S, Karthikeyan C, Moorthy NSHN, Trivedi P (2004) QSAR modelling of HIV-1 reverse transcriptase inhibition by benzoxazinones using a combination of P_VSA and pharmacophore feature descriptors. Bioorg Med Chem Lett 14:6089\u20136094","journal-title":"Bioorg Med Chem Lett"},{"key":"9510_CR4","first-page":"189","volume":"i","author":"N Balasubramanian","year":"2007","unstructured":"Balasubramanian N, Avinash D, Vishnukant M (2007) QSAR studies of 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridines as potent angiotensin II receptor antagonists by MLR and NLR analysis. ARKIVOC i:189\u2013204","journal-title":"ARKIVOC"},{"key":"9510_CR5","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2174\/0929867054020981","volume":"12","author":"NM Cerqueira","year":"2005","unstructured":"Cerqueira NM, Pereira S, Fernandes PA, Ramos MJ (2005a) Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumor therapy. Curr Med Chem 12:1283\u20131294","journal-title":"Curr Med Chem"},{"issue":"11","key":"9510_CR6","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2174\/0929867054020981","volume":"12","author":"NMFSA Cerqueira","year":"2005","unstructured":"Cerqueira NMFSA, Pereira S, Fernandes PA, Ramos MJ (2005b) Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumour therapy. Curr Med Chem 12(11):1283\u20131294","journal-title":"Curr Med Chem"},{"issue":"42","key":"9510_CR7","doi-asserted-by":"crossref","first-page":"21272","DOI":"10.1021\/jp0608269","volume":"110","author":"NMFSA Cerqueira","year":"2006","unstructured":"Cerqueira NMFSA, Fernandes PA, Ramos MJ (2006) Enzyme ribonucleotide reductase: unraveling an enigmatic paradigm of enzyme inhibition by furanone derivatives. J Phys Chem B 110(42):21272\u201321281","journal-title":"J Phys Chem B"},{"key":"9510_CR8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/157489207779561408","volume":"2","author":"NMFSA Cerqueira","year":"2007","unstructured":"Cerqueira NMFSA, Fernandes PA, Ramos MJ (2007a) Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents. Recent Pat Anticancer Drug Discov 2:11\u201329","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"30","key":"9510_CR9","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.1002\/chem.200700260","volume":"13","author":"NMFSA Cerqueira","year":"2007","unstructured":"Cerqueira NMFSA, Fernandes PA, Ramos MJ (2007b) Understanding ribonucleotide reductase inactivation by gemcitabine. Chem Eur J 13(30):8507\u20138515","journal-title":"Chem Eur J"},{"key":"9510_CR10","unstructured":"Chem BioOffice (2008) CambridgeSoft Corp, UK"},{"issue":"365","key":"9510_CR11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2307\/2286747","volume":"74","author":"RD Cook","year":"1979","unstructured":"Cook RD (1979) Influential observation in linear regression. J Am Stat Assoc 74(365):169\u2013174","journal-title":"J Am Stat Assoc"},{"issue":"1\u20132","key":"9510_CR12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0166-1280(99)00360-7","volume":"503","author":"G Cruciani","year":"2000","unstructured":"Cruciani G, Crivori P, Carrupt PA, Testa B (2000a) Molecular fields in quantitative structure permeation relationships: the Volsurf approach. J Mol Struct Theochem 503(1\u20132):17\u201330","journal-title":"J Mol Struct Theochem"},{"issue":"2","key":"9510_CR13","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0928-0987(00)00162-7","volume":"11","author":"G Cruciani","year":"2000","unstructured":"Cruciani G, Pastor M, Guba W (2000b) Volsurf: a new tool for the pharmacokinetic optimization of lead compounds. Eur J Pharm Sci 11(2):S29\u2013S39","journal-title":"Eur J Pharm Sci"},{"key":"9510_CR14","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0166-3542(99)00070-4","volume":"44","author":"A Das","year":"1999","unstructured":"Das A, Trousdale MD, Ren SJ, Lien EJ (1999) Inhibition of herpes simplex virus type 1 and adenovirus type 5 by heterocyclic Schiff bases of aminohydroxyguanidine tosylate. Antiviral Res 44:201\u2013208","journal-title":"Antiviral Res"},{"key":"9510_CR15","first-page":"409","volume":"37","author":"J Durbin","year":"1950","unstructured":"Durbin J, Watson GS (1950) Testing for serial correlation in least squares regression, I. Biometrika 37:409\u2013428","journal-title":"Biometrika"},{"key":"9510_CR16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/biomet\/38.1-2.159","volume":"38","author":"J Durbin","year":"1951","unstructured":"Durbin J, Watson GS (1951) Testing for serial correlation in least squares regression, II. Biometrika 38:159\u2013179","journal-title":"Biometrika"},{"key":"9510_CR17","doi-asserted-by":"crossref","first-page":"6343","DOI":"10.1021\/jm060232u","volume":"49","author":"J Easmon","year":"2006","unstructured":"Easmon J, Purstinger G, Thies KS, Heinisch G, Hofmann J (2006) Synthesis, structure\u2013activity relationship and antitumor studies of 2-benzoxazolyl hydrazones derived from alpha-(N)-acyl heteroatoms. J Med Chem 49:6343\u20136350","journal-title":"J Med Chem"},{"key":"9510_CR18","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1289\/ehp.5758","volume":"111","author":"L Erikkson","year":"2003","unstructured":"Erikkson L, Jaworsha J, Worth AP, Mark TDC, Robert MM, Gramatica P (2003) Methods for reliability and uncertainty assessment and for applicability evaluation of classification and regression based QSARs. Environ Health Perspect 111:1361\u20131375","journal-title":"Environ Health Perspect"},{"key":"9510_CR19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/i8020145","volume":"8","author":"E Erol","year":"2007","unstructured":"Erol E, Hasan T, Semra G, Selami P, Oral O (2007) A DFT-based QSARs study of acetazolamide\/sulfanilamide derivatives with carbonic anhydrase (CA-II) isozyme inhibitory activity. Int J Mol Sci 8:145\u2013155","journal-title":"Int J Mol Sci"},{"issue":"20","key":"9510_CR20","doi-asserted-by":"crossref","first-page":"6311","DOI":"10.1021\/ja0208613","volume":"125","author":"PA Fernandes","year":"2003","unstructured":"Fernandes PA, Ramos MJ (2003) Theoretical studies on the mechanism of inhibition of ribonucleotide reductase by (E)-2\u2032-fluromethylene-2\u2032-deoxycitidine-5\u2032-diphosphate. J Am Chem Soc 125(20):6311\u20136322","journal-title":"J Am Chem Soc"},{"key":"9510_CR21","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0006-2952(99)00419-0","volume":"59","author":"RA Finch","year":"2000","unstructured":"Finch RA, Liu M, Grill SP, Rose WC, Loomis R, Vasquez KM, Cheng Y, Sartorelli AC (2000) Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarba-zone): a potent inhibitor of ribonucleotide reductase activity with broad-spectrum antitumor activity. Biochem Pharmacol 59:983\u2013991","journal-title":"Biochem Pharmacol"},{"key":"9510_CR22","doi-asserted-by":"crossref","unstructured":"Gasteiger J, Marsili M (1980) Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges. Tetrahedron 36:3219\u20133228. http:\/\/www.who.int\/cancer\/en\/","DOI":"10.1016\/0040-4020(80)80168-2"},{"key":"9510_CR23","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.chemosphere.2006.03.067","volume":"65","author":"L Iglika","year":"2006","unstructured":"Iglika L, Andrew PW, Tatiana IN, John CD, Mark TDC (2006) Quantitative structure activity\u2013activity and quantitative structure\u2013activity investigations of human and rodent toxicity. Chemosphere 65:1878\u20131887","journal-title":"Chemosphere"},{"issue":"1","key":"9510_CR24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/14756360701810355","volume":"24","author":"C Karthikeyan","year":"2009","unstructured":"Karthikeyan C, Moorthy NSHN, Piyush T (2009) QSAR study of substituted 2-pyridinyl quanidine as selective urokinase-type plasminogen activator (uPA) inhibitors. J Enzyme Inhib Med Chem 24(1):6\u201313","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"1\u20132","key":"9510_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbapap.2004.02.007","volume":"1699","author":"M Kolberg","year":"2004","unstructured":"Kolberg M, Kolberg M, Strand KR, Graff P, Andersson KK (2004) Structure, function and mechanism of ribonucleotide reductases. Biochim Biophys Acta 1699(1\u20132):1\u201334","journal-title":"Biochim Biophys Acta"},{"key":"9510_CR26","first-page":"1","volume":"31","author":"EJ Lien","year":"1987","unstructured":"Lien EJ (1987) Ribonucleotide reductase inhibitors as anticancer and antiviral agents. Prog Drug Res 31:1\u201326","journal-title":"Prog Drug Res"},{"key":"9510_CR27","unstructured":"Lin A (2002) QuaSAR-descriptors. Chemical Computing Group Inc. Montreal, H3A 2R7 Canada. http:\/\/www.chemcomp.com\/Journal_of_CCG\/Features\/descr.htm"},{"key":"9510_CR28","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1016\/j.bmcl.2006.04.023","volume":"16","author":"BB Lohray","year":"2006","unstructured":"Lohray BB, Gandhi N, Srivastava BK, Lohray VB (2006) 3D QSAR studies of N-4-arylacryloylpiperazin-1-yl-phenyl-oxazolidinones: a novel class of antibacterial agents. Bioorg Med Chem Lett 16:3817\u20133823","journal-title":"Bioorg Med Chem Lett"},{"key":"9510_CR29","unstructured":"MOE 2007.02 (2007) Chemical Computing Group Inc., Montreal, H3A 2R7 Canada. http:\/\/www.chemcomp.com"},{"key":"9510_CR30","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1063\/1.1749394","volume":"2","author":"RS Mulliken","year":"1934","unstructured":"Mulliken RS (1934) A new electron affinity scale; together with data on valence states and on valence ionization potentials and electron affinities. J Chem Phys 2:782\u2013793","journal-title":"J Chem Phys"},{"key":"9510_CR31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1040-8428(98)00032-8","volume":"29","author":"P Navarra","year":"1999","unstructured":"Navarra P, Preziosi P (1999) Hydroxyurea: new insights on an old drug. Crit Rev Oncol Hematol 29:249\u2013255","journal-title":"Crit Rev Oncol Hematol"},{"key":"9510_CR32","volume-title":"Applied linear statistical models: regression, analysis of variance, and experimental designs","author":"J Neter","year":"1990","unstructured":"Neter J, Wasserman W, Kunter MH (1990) Applied linear statistical models: regression, analysis of variance, and experimental designs, 3rd edn. Irwin, Homewood, IL","edition":"3"},{"key":"9510_CR33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/1040-8428(95)00187-5","volume":"22","author":"G Nocentini","year":"1996","unstructured":"Nocentini G (1996) Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy. Crit Rev Oncol Hematol 22:89\u2013126","journal-title":"Crit Rev Oncol Hematol"},{"key":"9510_CR34","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1146\/annurev.biochem.75.103004.142443","volume":"75","author":"P Norlund","year":"2006","unstructured":"Norlund P, Reichard P (2006) Ribonucleotide reductase. Annu Rev Biochem 75:681\u2013706","journal-title":"Annu Rev Biochem"},{"key":"9510_CR35","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.bmcl.2005.02.035","volume":"15","author":"S Prasanna","year":"2005","unstructured":"Prasanna S, Manivannan E, Chaturvedi SC (2005) QSAR analyses of conformationally restricted 1,5-diaryl pyrazoles as selective COX-2 inhibitors: application of connection table representation of ligands. Bioorg Med Chem Lett 15:2097\u20132102","journal-title":"Bioorg Med Chem Lett"},{"key":"9510_CR36","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1021\/jm030016a","volume":"46","author":"AV Raichurkar","year":"2003","unstructured":"Raichurkar AV, Kulkarni VM (2003) Understanding the antitumor activity of novel hydroxysemicarbazide derivatives as ribonucleotide reductase inhibitors using CoMFA and CoMSIA. J Med Chem 46:4419\u20134427","journal-title":"J Med Chem"},{"key":"9510_CR37","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1021\/jm010252q","volume":"45","author":"S Ren","year":"2002","unstructured":"Ren S, Wang R, Komatsu K, Bonaz-Krause P, Zyrianov Y, McKenna EE, Csipke C, Tokes ZA, Lien EJ (2002) Synthesis, biological evaluation, and quantitative structure\u2013activity relationship analysis of new Schiff bases of hydroxysemicarbazide as potential antitumor agents. J Med Chem 45:410\u2013419","journal-title":"J Med Chem"},{"key":"9510_CR38","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s11135-006-9018-6","volume":"41","author":"MO Robert","year":"2007","unstructured":"Robert MO (2007) A caution regarding rules of thumb for variance inflation factors. Qual Quant 41:673\u2013690","journal-title":"Qual Quant"},{"key":"9510_CR39","unstructured":"Rotriquez G (1993\u20132000) Chapter 2, linear models for continuous data. 49\u201358. ( http:\/\/data.princeton.edu\/wws509\/notes )"},{"key":"9510_CR40","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2174\/156800906777723949","volume":"6","author":"J Shao","year":"2006","unstructured":"Shao J, Zhou B, Chu B, Yen Y (2006) Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets 6:409\u2013431","journal-title":"Curr Cancer Drug Targets"},{"key":"9510_CR41","doi-asserted-by":"crossref","unstructured":"Statistica 8.0 statistical software (2007) StatSoft, Inc. USA","DOI":"10.1016\/S1359-6128(07)70024-1"},{"key":"9510_CR42","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3109\/10408369709006424","volume":"34","author":"T Szekeres","year":"1997","unstructured":"Szekeres T, Fritzer-Szekeres M, Elford HL (1997) The enzyme ribonucleotide reductase: target for antitumor and anti-HIV therapy. Crit Rev Clin Lab Sci 34:503\u2013528","journal-title":"Crit Rev Clin Lab Sci"},{"key":"9510_CR43","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2091-6-8","volume":"6","author":"R Tomas","year":"2005","unstructured":"Tomas R, Ossama BK, Barry SC (2005) Rational representation of ribonucleotide reductase activity. BMC Biochem 6:8","journal-title":"BMC Biochem"},{"key":"9510_CR44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/qsar.200390007","volume":"22","author":"A Tropsha","year":"2003","unstructured":"Tropsha A, Gramatica P, Gombar VK (2003) The importance of earnest, validation is the absolute essential application and interpretation of QSPR models. QSAR Comb Sci 22:69\u201377","journal-title":"QSAR Comb Sci"},{"key":"9510_CR45","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1586\/14737140.2.4.437","volume":"2","author":"AM Tsimberidou","year":"2002","unstructured":"Tsimberidou AM, Alvarado Y, Giles FJ (2002) Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies. Expert Rev Anticancer Ther 2:437\u2013448","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Medicinal Chemistry Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-010-9510-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00044-010-9510-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-010-9510-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T16:57:39Z","timestamp":1711990659000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00044-010-9510-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,2]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["9510"],"URL":"https:\/\/doi.org\/10.1007\/s00044-010-9510-3","relation":{},"ISSN":["1054-2523","1554-8120"],"issn-type":[{"value":"1054-2523","type":"print"},{"value":"1554-8120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,2]]}}}